#USA #San Francisco #Hagens Berman #MoonLake #SLK

Legal Investigation into MoonLake's Claims

In a striking turn of events, renowned plaintiffs' rights law firm Hagens Berman has launched an investigation into MoonLake Immunotherapeutics, particularly focusing on the efficacy claims surrounding its lead drug, SLK. Following a catastrophic plunge in its stock price—dropping approximately 90% from $61.99 to $6.24—the firm is seeking to uncover alleged misleading information provided to investors.

The Core Allegations

The investigation, spearheaded by lead partner Reed Kathrein, centers around whether MoonLake adequately disclosed the true effectiveness of SLK compared to its competitor, BIMZELX, a well-established monoclonal antibody approved by the FDA. The crux of the matter lies in the differences—or lack thereof—in clinical outcomes between SLK and BIMZELX, especially since both target interleukin-17 (IL-17).

“When biotech firms make claims regarding clinical trials, it’s essential that those assertions align with the actual data,” added Kathrein. The lawsuit suggests that the company intentionally withheld crucial facts about SLK's underwhelming performance during the Phase 3 VELA trials, leading potential investors to make decisions based on inflated claims.

Misrepresentation of Nanobody Structure

Hagens Berman's analysis reveals a significant focus on the alleged misrepresentation regarding the 'Nanobody' structure of SLK. MoonLake purported that its unique Nanobody would result in superior clinical outcomes for conditions such as hidradenitis suppurativa (HS). However, the firm’s investigation seeks to determine whether these claims were mistakenly optimistic, indicating that the Nanobody did not deliver a meaningful clinical advantage.

This alleged misinformation has critical implications for investors who purchased shares within the specified class period—from March 10, 2024, to September 29, 2025. For these investors, the 90% drop hints at hiding devastating truths about SLK's clinical performance.

Financial Ramifications and Next Steps

As the investigation progresses, the ethical obligations of MoonLake are under scrutiny. Hagens Berman is urging those who suffered significant financial losses to reach out. They assert that investors may be entitled to damages resulting from the alleged misconceptions perpetuated by the company.

In light of this, the deadline to file for lead plaintiff status is set for December 15, 2025. Investors are encouraged to contact Reed Kathrein for guidance and support regarding their potential claims.

Hagens Berman’s notable history—having secured upwards of $2.9 billion in settlements for investors in similar cases—places them in a strong position to advocate for those affected by the decline in MoonLake’s share value.

Investor Resources

The firm is also reaching out to whistleblowers who might possess non-public information pertinent to the case. Under new SEC regulations, these individuals could earn significant rewards for providing insight that leads to recovery.

As the investigation unfolds, Hagens Berman stands firm in its commitment to corporate accountability and protecting investor rights, emphasizing the importance of transparent communication from biotech firms.

For further details, including how to submit losses related to MoonLake’s stock, individuals can visit the law firm's secure online form or connect directly via phone or email for comprehensive assistance.

In these challenging times, affected investors must remain vigilant, seeking clarity amid the turbulence gleaned from the biotech industry's evolving landscape.